Ascorbic Acid Interaction With Analgesic Effect of Morphine and Tramadol in Mice

Fatemeh Zeraati 1, Malihe Araghchian 1, Mohammad Hadi Farjoo 1

1Department of Pharmacology, Hamedan University of Medical Sciences, Hamedan, Iran

Objectives: The purpose of the present study was to assess the nature of the interaction between ascorbic acid and two analgesic drugs, morphine and tramadol.

Materials and Methods: The analgesic activity was assessed by the acetic acid writhing test in male Naval Medical Research Institute (NMRI) mice. The results were obtained using four to six animals in each group. All the drugs were injected intraperitoneally. The effective doses (ED) that produced 20%, 50%, and 65% antinociception (ED20, ED50, and ED65) were calculated from the dose-response curve of each drug alone as well as co-administration of ascorbic acid and tramadol or morphine. The interaction index was calculated as experimental ED/theoretical ED. For each drug combination, ED20, ED50, and ED65 were determined by linear regression analysis of the dose-response curve, and they were compared to theoretical ED20, ED50, and ED65 using t-test.

Results: The antinociceptive effects of all drugs were dose-dependent (ED20 was 206.1 mg/kg for ascorbic acid, 8.33 mg/kg for tramadol, and 0.79 mg/kg for morphine). The interaction index demonstrated additive effects at ED20, ED50, and ED65 for co-administration of ascorbic acid and tramadol or morphine. However, at ED50, combination of ascorbic acid and tramadol or morphine showed synergic effects. The interaction index values of the combinations demonstrated the potency ratio of ascorbic acid/morphine to be lower than ascorbic acid/tramadol.

Conclusions: This study demonstrated the results of interactions between ascorbic acid and tramadol or morphine. The results showed that the interaction effects on antinociception may be synergic or additive, depending on the level of effect.

Keywords: Ascorbic Acid; Tramadol; Morphine

1. Background

Combining different analgesic drugs for improving the drug efficacy is a recommended strategy, intended to achieve optimal therapeutic effects. These strategies that are commonly used in almost all clinical settings are aimed to facilitate compliance in patients, simplify drug prescription, and decrease the drugs side effects, concomitant with increasing their efficacy (1, 2). In this context, concurrent administration of antinociceptive drugs can lead to achieving synergistic effects (3).

Several investigations have been carried out on physiological benefits of ascorbic acid and its applications as a therapeutic agent in various disease states. Furthermore, the beneficial effects of ascorbic acid as a cost-effective, convenient, and safe supplement for detoxifying narcotic drugs had been identified for many years (4). Regarding the antinociceptive effects of ascorbic acid, it was earlier reported that a single dose of ascorbic acid intraperitoneally can produce antinociception by interaction with ionotropic glutamate receptors (5). Moreover, a recent study demonstrated that plasma concentrations of ascorbic acid were lower in patients with neuralgia than in healthy volunteers and ascorbic acid treatment decreased the spontaneous pain in those patients (6, 7). It has been recently suggested that administration of ascorbic acid in combination with vitamin E can exert synergistc antinociceptive effects (8, 9) and it was reported that vitamin C exerted its antinociceptive effects primarily as a result of its antioxidant properties. It is clear that vitamin C has a major role in mitigating pain in a number of clinical conditions, in addition to postherpetic neuralgia (10).

However, a few studies have been conducted on additive or synergistic antinociceptive effects of ascorbic acid combined with other analgesics, especially opioid sub-
stances. Some studies could show that concurrent use of ascorbic acid decreased morphine consumption in postoperative periods (11). It has been hypothesized that inhibition of morphine tolerance and dependence development by ascorbic acid has two dopaminergic and glutamatergic components (12). However, a detailed evaluation of the combination of ascorbic acid and commonly used analgesics has not been reported.

2. Objectives

The purpose of the present study was to assess the nature of the interaction between ascorbic acid and two analgesic drugs, morphine and tramadol, in a rodent model of visceral pain.

3. Materials and Methods

Male Naval Medical Research Institute (NMRI) mice (25-30 g), housed on a 12-hour light-dark cycle at 22 ± 2°C with access to food and water, were used in this experimental survey. The experiments were performed in accordance with the Guidelines for the Care of Laboratory Animals and the ethical guidelines for investigation of experimental pain, approved by the research Committee of Hamedan University of Medical Sciences. The analgesic activity was assessed by the acetic acid abdominal constriction test (writhing test) (13). Mice were injected intraperitoneally (IP) with 10 mL/kg of 0.7% acetic acid solution, 30 minutes after the IP administration of the study drugs or normal saline as control, the time at which preliminary experiments showed occurrence of the maximum effect. A writh is characterized by a wave of contraction of the abdominal musculature followed by extension of the hind limbs. The number of writhes in a 10-minute period was counted, starting five minutes after the acetic acid administration. Antinociceptive activity was expressed as the inhibition percentage of the usual number of writhes in a drug-treated animal, compared to the mean number of writhes obtained in control animals in this study (14).

Dose-response curves for the antinociceptive effects of ascorbic acid, morphine, and tramadol were obtained, using at least four to six animals at each of at least four doses. The drugs were injected IP. A least squares linear regression analysis of the log dose-response curves allowed calculation of the dose that caused 50% antinociception (ED50) for each drug. Using this protocol, ED20, ED50, and ED80 were also calculated. A dose-response curve was also obtained by IP co-administration of ascorbic acid and morphine as well as ascorbic acid and tramadol in fixed combination ratios of their respective ED50, ED20, and ED10: 1/2, 1/4, 1/8, 1/16 (15). The theoretical additive ED50, obtained from the calculation, ED50 add, was calculated as: ED50 ascorbic acid/Pl + RP2, where R is the potency ratio of ascorbic acid and tramadol, of the combined drug alone, P1 is the proportion of ascorbic acid and P2 is the proportion of the combined drug in the total mixture (16). The potency ratio in each combination was obtained by ED50, ED20, or ED65 for morphine or tramadol/ED50, ED20, or ED65 for ascorbic acid, respectively (2). Supra-additivity or synergistic effect is defined as the effect of a drug combination which is statistically different. If the experimental ED is significantly lower than the theoretically calculated equi-effect of a drug combination with the same proportions, the effect of the combination is synergistic. Otherwise, the effect of the combination is additive and additivity means that each constituent contributes with its own potency to the total effect. The interaction index was calculated as experimental ED/theoretical ED. If the value is close to one, the interaction is additive. Values lower than one are an indication of the magnitude of supra-additive or synergistic interactions and values higher than one correspond to subadditive or antagonistic interactions (17). Furthermore, lower values indicate higher potency of the combinations.

The results were presented as means ± SD or ED50 values with 95% confidence limits (95% CL). The statistical difference between theoretical and experimental values was assessed by student’s t-test for independent means and P values less than 0.05 were considered significant.

4. Results

The number of animals was kept at a minimum, compatible with consistent effects of the drug treatments. A few mice had no response to acetic acid and did not show writhes; so, they were omitted and replaced by new ones. The ED50, ED20, and ED80 values and 95% CL for ascorbic acid, respectively (2). Analgesic drugs, morphine and tramadol, in a rodent model of visceral pain.

Table 1. ED50, ED20, and ED65 Values with 95% Confidence Limits for Antinociceptive Effects of Ascorbic Acid, Morphine, and Tramadol in the Writhing Test of Mice a

| ED   | ED, mg/kg (CL) |
|------|----------------|
| ED50 | Ascorbic acid  | 206.1 (179.1-237.2) |
|      | Tramadol       | 8.33 (6.91-10.09)  |
|      | Morphine       | 0.79 (0.58-1.09)   |
| ED20 | Ascorbic acid  | 82.56 (23.60-288.8) |
|      | Tramadol       | 3.28 (1.75-6.16)   |
|      | Morphine       | 0.14 (2.60-1.25)   |
| ED65 | Ascorbic acid  | 300.50 (218.0-413.2) |
|      | Tramadol       | 24.40 (13.01-45.74) |
|      | Morphine       | 2.70 (2.21-3.29)   |

a Abbreviations: CL, confidence limit; ED, Effective Dose.
Table 2. Theoretical and Experimental ED<sub>50</sub>, ED<sub>20</sub>, and ED<sub>65</sub> Values with 95% Confidence Limits and Ratios for Combinations of Ascorbic Acid with Morphine and Tramadol in the Writhing Test of Mice<sup>a</sup>

| ED and Combination | Theoretical | Experimental | Ratio |
|--------------------|-------------|--------------|-------|
| TR/AA | 107.22 (93.00-123.62) | 102.88 (80.86-149.42) | 1:24.7 |
| MO/AA | 103.44 (89.84-119.14) | 105.13 (74.79-144.01) | 1:260.89 |
| TR/AA | 49.92 (12.68-14.48) | 29.74 (19.38-45.00) | 1:24.7 |
| MO/AA | 41.35 (10.50-145.03) | 29.12 (23.73-35.73) | 1:260.89 |
| TR/AA | 162.45 (115.76-229.47) | 145.05 (115.77-181.74) | 1:24.7 |
| MO/AA | 151.60 (110.36-208.24) | 139.58 (56.09-348.55) | 1:260.89 |

<sup>a</sup> Abbreviations: AA, ascorbic acid; CL, confidence limit; ED, Effective Dose; MO, morphine; TR, tramadol.

Table 3. Interaction Index of the Combinations of Ascorbic Acid and Morphine or Tramadol in the Writhing Test of Mice<sup>a</sup>

| ED | Interaction Index | P Value |
|----|------------------|---------|
| ED<sub>50</sub> | | |
| AA/TR | 0.96 | 0.27 |
| AA/MO | 1.016 | 0.19 |
| ED<sub>20</sub> | | |
| AA/TR | 0.69 | 0.009 |
| AA/MO | 0.70 | 0.008 |
| ED<sub>65</sub> | | |
| AA/TR | 0.89 | 0.81 |
| AA/MO | 0.92 | 0.64 |

<sup>a</sup> Abbreviations: AA, ascorbic acid; ED, Effective Dose; MO, morphine; TR, tramadol.

The antinociceptive activity of IP co-administration of fixed combination ratios of ED<sub>50</sub>, ED<sub>20</sub>, and ED<sub>65</sub> of morphine or tramadol and ascorbic acid was assessed by calculating the ED<sub>50</sub>, ED<sub>20</sub>, and ED<sub>65</sub> of the mixtures from the corresponding dose-response curves.

Table 2 shows the theoretical and experimental ED<sub>50</sub>, ED<sub>20</sub>, and ED<sub>65</sub> values for the combinations, with their 95% CL and fixed ratios.

Table 3 shows the interaction index of the combination of ascorbic acid and tramadol, administered IP, which resulted in additive interactions at ED<sub>50</sub> and ED<sub>65</sub>, while led to synergistic interactions at ED<sub>20</sub>. The interaction index of the combination of ascorbic acid and morphine showed additive interactions at ED<sub>50</sub> and ED<sub>65</sub>; however, synergistic interaction was found to ED<sub>20</sub> obtained from the dose-response curves. Furthermore, the interaction index values of the IP combinations demonstrated the potency rate of ascorbic acid/morphine to be lower than ascorbic acid/tramadol.

5. Discussion

This study revealed some important findings. First, the antinociceptive effects of three drugs were dose-dependent with different potencies. We wanted to identify the possible antagonism and synergism in presence of high and low levels of antinociception.

Furthermore, using different ED values, combination of ascorbic acid and morphine or tramadol had different interactions, either additive or synergistic, so that the combinations resulted in synergistic interactions at ED<sub>20</sub>, but led to additive interaction at ED<sub>50</sub> and ED<sub>65</sub>. It has been reported that tramadol and methimazole had antagonism at ED20, whereas at ED<sub>50</sub> and ED<sub>80</sub> they showed synergy. The mechanism of interaction has been unknown (18).

Finally and according to the interaction index value, co-administration of ascorbic acid/tramadol had higher potency rate in comparison with that of ascorbic acid and morphine. As shown in a study supplementation with ascorbic acid decreased morphine consumption in the postoperative period, in patients undergoing laparoscopic cholecystectomy (9). It has been demonstrated that local perfusion of morphine can produce increased levels of extracellular ascorbic acid in nervous system of animal models and this morphine-induced changes in ascorbic acid can be mediated by the release of γ-aminobutyric acid (GABA) and dopamine (DA) as well as activation of these hormones specific receptors (19). This effect can also change the motivational processes underlying morphine self-administration. Previous studies have shown that co-administration of morphine and other drugs produced different interactions. Selective imidazoline I<sub>1</sub> receptor ligands have substantial antinociceptive effects and produce antinociceptive synergy with morphine in a rat model with acute pain (20).

The interaction between morphine and nicotine is additive (21). Morphine and gabapentin have shown antinociceptive synergism in relieving the neuropathic pain induced by chronic constriction injury (22) and ascorbic
acid can decrease morphine self-administration and withdrawal symptoms in rats (23). Tramadol has a central analgesic effect and its mechanism is mainly based on serotonin reuptake inhibition (24). It can also inhibit the norepinephrine transporter function (25). The ability of tramadol to create analgesic effect is partly through activating the opioid receptors, indicating that the dose-response curves of these two types of drugs are not parallel.

Combination of tramadol and acetaminophen for painful diabetic neuropathy in streptozotocin-induced diabetic rats produces an additive antinociceptive effect (26). Tramadol and caffeine combination showed synergistic interactions on the antinociception measured in a formalin model (27). Our results showed that the interaction between ascorbic acid and morphine or tramadol on antinociception may be synergistic or additive, depending on the level of effect. Additivity could be demonstrated at 50% or higher levels of the effect.

Different levels of potency ratios can also explain their different pharmacological pathways, which should be more evaluated in further studies. The analysis of antinociceptive efficacies produced by co-administration of ascorbic acid and morphine or tramadol for different levels of nociception, revealed that co-administration provided better antinociceptive coverage than the individual drugs. There is neither a simple explanation for the mechanism of interaction between the two drugs, nor for the type of interaction at different levels of the antinociceptive effect. We had different effects (additive or synergistic) of ascorbic acid in different EDs of analgesics with unknown reasons. We need further researches to determine the mechanism of this interaction. Findings of the present work can be very important, because in clinical settings, combinations of ascorbic acid and tramadol or morphine can decrease the high postoperative dosages of administered opiates, and thus, can lead to less drug side effects.

Authors’ Contributions

Study concept and design: Fatemeh Zeraati and Mahli Aragchian; acquisition of data: Mahli Aragchian; analysis and interpretation of data: Mohammad Hadi Farjooy; drafting of the manuscript: Fatemeh Zeraati; critical revision of the manuscript for important intellectual content: Fatemeh Zeraati; statistical analysis: Mohammad Hadi Farjooy; administrative, technical, and material support: Mahli Aragchian; study supervision: Fatemeh Zeraati.

Funding/Support

This work was financially supported by the Vice Chancellor for Research, Hamedan University of Medical Sciences, Hamedan, Iran.

References

1. Miranda HF, Pinardi G. Isobolographic analysis of the antinociceptive interactions of clonidine with nonsteroidal anti-inflammatory drugs. Pharmacol Res. 2004;50(3):273-8.
2. Miranda HF, Puig MM, Prieto JC, Pinardi G. Synergism between paracetamol and nonsteroidal anti-inflammatory drugs in experimental acute pain. Pain. 2006;131(2):222-8.
3. Hyllested M, Jones S, Pedersen JL, Kehlet H. Comparative effect of paracetamol, NSAIDs or their combination in postoperative pain management: a qualitative review. Br J Anaesth. 2002;88(2):199-214.
4. Free V, Sanders P. The use of ascorbic acid and mineral supplements in the detoxification of narcotic addicts. J Psychopharmacol. 1979;1(3):27-22.
5. Rosa KA, Gadotti VM, Rosa AO, Rodrigues AL, Calixto JB, Santos AR. Evidence for the involvement of glutamatergic system in the antinociceptive effect of ascorbic acid. Neurosci Lett. 2005;381(1-2):185-8.
6. Chen JY, Chang CY, Feng PH, Chu CC, So EC, Hu ML. Plasma vitamin C is lower in postherpetic neuralgial patients and administration of vitamin C reduces spontaneous pain but not brush-evoked pain. Clin J Pain. 2009;25(7):562-9.
7. Peek DF, van Zundert J. The vitamin C controversy. Clin J Pain. 2010;26(6):551-2.
8. Li R, Kallenborn-Gerhardt W, Geisslinger G, Schmidtko A. Additive antinociceptive effects of a combination of vitamin C and vitamin E after peripheral nerve injury. PLoS One. 2011;6(12).
9. Park JM, Kim CK, Lee HC, Jung H, Choi KU, Hong SW, et al. Antialloodynic effects of vitamin C and vitamin E in chronic post-ischemia pain rat model. Korean J Anesthesiol. 2013;65(5):442-8.
10. Kapoor S. Vitamin C and its emerging role in pain management: beneficial effects in pain conditions besides post herpetic neuralgia. Korean J Pain. 2012;25(5):320-4.
11. Kanazi GE, El-Khatib MF, Yazbeck-Karam VG, Hanna JE, Masri B, Aouad MT. Effect of vitamin C on morphine use after laparoscopic cholecystectomy: a randomized controlled trial. Can J Anaesth. 2012;59(5):538-43.
12. Kulkarni SK, Deshpande C, Dhiri A. Ascorbic Acid inhibits development of tolerance and dependence to opiates in mice: possible glutamatergic or dopaminergic modulation. Indian J Pharm Sci. 2008;70(1):56-60.
13. Hayashi G, Takemori AE. The type of analgesic-receptor interaction involved in certain analgesic assays. Eur J Pharmacol. 1979;61(1):63-6.
14. Miranda HF, Pinardi G. Antinociception, tolerance, and physical dependence comparison between morphine and tramadol. Pharmacol Biochem Behav. 1998;64(4):357-60.
15. Miranda HF, Sierraizta F, Pinardi G. Neostigmine interactions with non steroidal anti-inflammatory drugs. Br J Pharmacol. 2002;133(7):1591-7.
16. Tallarida RJ. Drug synergism: its detection and applications. J Pharmacol Exp Ther. 2001;306(3):365-72.
17. Tallarida RJ, Stone DJ, Raffa RB. Efficient designs for studying synergistic drug combinations. Life Sci. 1997;61(26):257-17.
18. Poveda R, Planas E, Pol O, Romero A, Sanchez S, Puig MM. Interaction between metamizol and tramadol in a model of acute visceral pain in rats. Eur J Pain. 2001;5(5):439-48.
19. Sun JF, Yang JF, Wang F, Hou Y, Dong YX, Wu CF. GABA receptors in VTA mediate the morphine-induced release of ascorbic acid in rat nucleus accumbens. Brain Res. 2010;1385(2):52-8.
20. Sanchez-Blazquez P, Boronat MA, Olmos G, Garcia-Sevilla JA, Garzon J. Activation of [2+]imidazoline receptors enhances supraspinal morphine analgesia in mice: a model to detect agonist and antagonist activities at these receptors. Br J Pharmacol. 2009;150(4):146-52.
21. Li X, Li JX, France CP. Interactions between morphine, scopolamine and nicotine: schedule-controlled responding in rats. Pharmacol Biochem Behav. 2010;96(1):91-5.
22. De la OM, Diaz-Reval MJ, Cortes-Arooyo AR, Dominguez-Ramirez AM, Lopez-Munoz FJ. Anti-nociceptive synergism of morphine and gabapentin in neuropathic pain induced by chronic constriction injury. Pharmacol Biochem Behav. 2009;92(2):547-64.
23. Alaei H, Esmaeili M, Nasimi A, Pourshahzad A. Ascorbic acid decreases morphine selfadministration and withdrawal symptoms in rats. Pathophysiol. 2005;12(2):103-7.
24. Reimann W, Schneider F. Induction of 5-hydroxytryptamine release by tramadol, fenfluramine and resepin. Eur J Pharmacol. 1998;349(1-2):199-203.
25. Sagata K, Minami K, Yanagihara N, Shiraishi M, Toyohira Y, Ueno S, et al. Tramadol inhibits norepinephrine transporter function at desipramine-binding sites in cultured bovine adrenal medullary cells. Anesth Analg. 2002;94(4):901–6.

26. Gong YH, Yu XR, Liu HL, Yang N, Zuo PP, Huang YG. Antinociceptive effects of combination of tramadol and acetaminophen on painful diabetic neuropathy in streptozotocin-induced diabetic rats. Acta Anaesthesiol Taiwan. 2011;49(1):16–20.

27. Diaz-Reval MI, Carrillo-Munguia N, Martinez-Casas M, Gonzalez-Trujano ME. Tramadol and caffeine produce synergistic interactions on antinociception measured in a formalin model. Pharmacol Biochem Behav. 2010;97(2):357–62.